12:00 AM
May 21, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tasquinimod: Additional Phase II data

Additional data from a double-blind, international Phase II trial in 206 asymptomatic, metastatic CRPC patients showed that oral tasquinimod led to median overall survival (OS) of 34.2 months vs. 30.2 months for placebo. In a subgroup of CRPC patients with bone metastases (n=136), median OS was 34.2 months for tasquinimod vs. 25.6 months for placebo. Additionally, time to symptomatic progression was significantly longer in patients treated with tasquinimod vs. placebo (p=0.039)....

Read the full 333 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >